JNK-9L

JNK-9L (Compound 9l) is a BBB-penetrable and ATP-competitive JNK inhibitor with IC50s of 0.099 and 0.148 μM for JNK1 and JNK3, respectively. JNK-9L significantly inhibits c-jun phosphorylation and Streptozotocin (HY-13753) -induced ROS generation with an IC50 of 0.8 nM. JNK-9L can be used for neurodegenerative disorders like Parkinson’s disease research[1].

Product Specifications

CAS Number

[1128096-64-9]

UNSPSC

12352005

Target

JNK; Reactive Oxygen Species (ROS)

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Purity

98.06

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

FC1=CC(C2=NC(NC(C=C3)=CC=C3N4C=NC(N5CCOCC5)=N4)=NC=C2)=CC(N6CCOCC6)=C1

Molecular Formula

C26H27FN8O2

Molecular Weight

502.54

References & Citations

[1]Kamenecka T, et al. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. J Med Chem. 2010 Jan 14;53 (1) :419-31.